## Kirsi Pylvänäinen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9288200/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet, The, 2011, 378, 2081-2087.	6.3	849
2	Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut, 2017, 66, 464-472.	6.1	411
3	Cancer risk and survival in <i>path_MMR</i> carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 2018, 67, 1306-1316.	6.1	410
4	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genetics in Medicine, 2020, 22, 15-25.	1.1	365
5	Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet, The, 2020, 395, 1855-1863.	6.3	220
6	Development of Colorectal Tumors in Colonoscopic Surveillance in Lynch Syndrome. Gastroenterology, 2007, 133, 1093-1098.	0.6	131
7	Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut, 2017, 66, 1657-1664.	6.1	127
8	No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies. Gastroenterology, 2018, 155, 1400-1409.e2.	0.6	112
9	Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet Oncology, The, 2012, 13, 1242-1249.	5.1	95
10	Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. Gastroenterology, 2020, 158, 1326-1333.	0.6	60
11	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncology, The, 2021, 22, 1014-1022.	5.1	58
12	Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report. Hereditary Cancer in Clinical Practice, 2017, 15, 18.	0.6	49
13	Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 8.	0.6	42
14	Compliance and Satisfaction with Long-Term Surveillance in Finnish HNPCC Families. Familial Cancer, 2006, 5, 175-178.	0.9	39
15	Sharing genetic risk with next generation: mutation-positive parents' communication with their offspring in Lynch Syndrome. Familial Cancer, 2011, 10, 43-50.	0.9	39
16	Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Genetics in Medicine, 2021, 23, 705-712.	1.1	28
17	Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 28.	0.6	27
18	Causes of death of mutation carriers in Finnish Lynch syndrome families. Familial Cancer, 2012, 11, 467-471.	0.9	26

KIRSI PYLVÃNAŘ

#	Article	IF	CITATIONS
19	Psychosocial consequences of predictive genetic testing for lynch syndrome and associations to surveillance behaviour in a 7-year follow-up study. Familial Cancer, 2013, 12, 639-646.	0.9	23
20	Endometrial cancer risk factors among Lynch syndrome women: a retrospective cohort study. British Journal of Cancer, 2016, 115, 375-381.	2.9	19
21	Uptake of genetic testing by the children of Lynch syndrome variant carriers across three generations. European Journal of Human Genetics, 2017, 25, 1237-1245.	1.4	13
22	Comparison of lifestyle, hormonal and medical factors in women with sporadic and Lynch syndrome-associated endometrial cancer: A retrospective case-case study. Molecular and Clinical Oncology, 2017, 6, 758-764.	0.4	11
23	Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. European Journal of Cancer, 2021, 148, 124-133.	1.3	11
24	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. Journal of Clinical Medicine, 2021, 10, 2856.	1.0	11
25	Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum. International Journal of Cancer, 2021, 148, 512-513.	2.3	9
26	Body Weight, Physical Activity, and Risk of Cancer in Lynch Syndrome. Cancers, 2021, 13, 1849.	1.7	6
27	Factors associated with decision-making on prophylactic hysterectomy and attitudes towards gynecological surveillance among women with Lynch syndrome (LS): a descriptive study. Familial Cancer, 2020, 19, 177-182.	0.9	5
28	Testing for Lynch Syndrome in Endometrial Carcinoma: From Universal to Age-Selective MLH1 Methylation Analysis. Cancers, 2022, 14, 1348.	1.7	3
29	Descriptive study on subjective experience of genetic testing with respect to relationship, family planning and psychosocial wellbeing among women with lynch syndrome. Hereditary Cancer in Clinical Practice, 2021, 19, 38.	0.6	2